David A. Chazanovitz Named President and Chief Operating Officer of Cambridge Heart, Inc.; Jeffrey M. Arnold to Continue as Chairman and CEO.

Business Editors & Health/Medical Writers

BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 11, 2000

Cambridge Heart, Inc. (NASDAQ: CAMH) today announced that David A. Chazanovitz will join the Company as President and Chief Operating Officer and will be responsible for the day to day operations of the Company. Jeffrey M. Arnold, formerly Chairman of the Board, President and Chief Executive Officer will remain as Chairman and Chief Executive Officer of the Company.

Mr. Chazanovitz joins Cambridge Heart with 28 years experience in sales, marketing and general management of medical products businesses, ranging from early stage device companies to larger more established businesses. As former President of the C. R. Bard Electrophysiology division he has direct knowledge of Cambridge Heart's customers and markets.

"With our new Heartwave product enjoying a very positive response from the marketplace, Cambridge Heart needs now to focus on marketing, managing rapid growth and as well as nurturing important third party relationships," stated Jeffrey M. Arnold, Company Chairman and CEO. "David Chazanovitz is a very accomplished president with a solid track record of developing successful marketing strategies for new medical products and growing sales organizations. He adds strength and depth to our management team at an important turning point for the Company. We are very pleased to add him to our team."

Mr Chazanovitz stated, "Cambridge Heart is an exciting opportunity for me. With the release of the Heartwave product the Company is now poised to transition its primary focus from R&D to Sales and Marketing. I am looking forward to accelerating the adoption of T-wave alternans into everyday clinical practice and thereby bring value to clinicians, patients and shareholders."

For the past five years Mr. Chazanovitz has worked as a Divisional President for NMT Medical, initially with total responsibility for establishing a start-up effort to develop a new cardiac technology and more recently as President of their $35 million Neurosciences Division. Mr. Chazanovitz has also held the position of President for several divisions of C.R. Bard, Inc., including Bard Ventures, Bard Electrophysiology Division and USCI Angiography Division. Earlier in his career he served as a Sales Executive at Forest Laboratories and Burroughs Wellcome, Co.

Mr. Chazanovitz earned a Bachelor of Science degree in Biology from City College of New York and an MBA in Marketing from Long Island University.

About Cambridge Heart, Inc.

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest, the early detection of coronary artery disease, and the prompt and accurate diagnosis of heart attack. The Company, started in 1992, is based in Bedford, Mass., and is traded on the NASDAQ/NMS under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.

Statements made in this press release that are not historical facts include forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include uncertainties associated with regulatory approval processes and other factors that are included in Cambridge Heart's Annual Report on Form 10-K for the year ending December 31, 1999 and Report form 10-Q for the quarter ending June 30, 2000.